Severe Hyperkalemia Rare Despite Dual RAAS Blockade
Analysis of data from the HALT PKD trial showed that 0% to 0.4% of patients experienced potassium levels above 6.5 mEq/L.
Analysis of data from the HALT PKD trial showed that 0% to 0.4% of patients experienced potassium levels above 6.5 mEq/L.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Veteran patients with levels below 100 mg/dL had a 26% higher risk of mortality compared with patients with triglyceride levels of 150-200 mg/dL.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
It develops in 8% of patients overall and 15.1% of patients with stage 5 CKD.
Increased risk observed in the VA health system unlikely to be fully explained by disparities in access to care.
Up to 100 mg per day raises plasma concentrations of ascorbic acid without increasing oxalate levels.
In a 24-hour exploratory trial, all 7 patients who wore the device remained hemodynamically stable over the study period.
In an 8-week randomized trial, extended-release nalbuphine 120 mg BID significantly reduced itch severity compared with placebo.
Please login or register first to view this content.